Find Icosapent Ethyl manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Related ProductsRelated Products

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

EU WC

0

NDC API

0

VMF

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

USP

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

86RELATED EXCIPIENT COMPANIES

142EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Exclusivities

GLOBAL SALES INFORMATION

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: Timnodonic acid, Icosapent, 10417-94-4, Icosapentaenoic acid, Epa, Cis-5,8,11,14,17-eicosapentaenoic acid
Molecular Formula
C20H30O2
Molecular Weight
302.5  g/mol
InChI Key
JAZBEHYOTPTENJ-JLNKQSITSA-N
FDA UNII
AAN7QOV9EA

Icosapent Ethyl
Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families.
1 2D Structure

Icosapent Ethyl

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoic acid
2.1.2 InChI
InChI=1S/C20H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h3-4,6-7,9-10,12-13,15-16H,2,5,8,11,14,17-19H2,1H3,(H,21,22)/b4-3-,7-6-,10-9-,13-12-,16-15-
2.1.3 InChI Key
JAZBEHYOTPTENJ-JLNKQSITSA-N
2.1.4 Canonical SMILES
CCC=CCC=CCC=CCC=CCC=CCCCC(=O)O
2.1.5 Isomeric SMILES
CC/C=C\C/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O
2.2 Other Identifiers
2.2.1 UNII
AAN7QOV9EA
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 5,8,11,14,17-eicosapentaenoic Acid

2. 5,8,11,14,17-icosapentaenoic Acid

3. Acid, Eicosapentanoic

4. Eicosapentanoic Acid

5. Icosapent

6. Omega 3 Eicosapentaenoic Acid

7. Omega-3-eicosapentaenoic Acid

8. Timnodonic Acid

2.3.2 Depositor-Supplied Synonyms

1. Timnodonic Acid

2. Icosapent

3. 10417-94-4

4. Icosapentaenoic Acid

5. Epa

6. Cis-5,8,11,14,17-eicosapentaenoic Acid

7. (5z,8z,11z,14z,17z)-icosa-5,8,11,14,17-pentaenoic Acid

8. Icosapento

9. Icosapentum

10. 5,8,11,14,17-eicosapentaenoic Acid

11. Eicosapentaenoate

12. 5z,8z,11z,14z,17z-eicosapentaenoic Acid

13. (all-z)-5,8,11,14,17-eicosapentaenoic Acid

14. Icosapent [inn]

15. (5z,8z,11z,14z,17z)-5,8,11,14,17-eicosapentaenoic Acid

16. 5,8,11,14,17-icosapentaenoic Acid

17. Ropufa 70

18. Ccris 3279

19. Incromega E 7010sr

20. Aan7qov9ea

21. (5z,8z,11z,14z,17z)-icosapentaenoic Acid

22. (5z,8z,11z,14z,17z)-eicosapentaenoic Acid

23. Omega-3-carboxylic Acids

24. Epa 45g

25. Chembl460026

26. (5z,8z,11z,14z,17z)-eicosapentaenoate

27. All-cis-5,8,11,14,17-icosapentaenoic Acid

28. Chebi:28364

29. All-cis-5,8,11,14,17-eicosapentaenoic Acid

30. All-cis-icosa-5,8,11,14,17-pentaenoic Acid

31. Icosapent (inn)

32. Cis-delta(5,8,11,14,17)-eicosapentaenoic Acid

33. 5,8,11,14,17-eicosapentaenoic Acid, (all-z)-

34. All-cis-fatty Acid 20:5 Omega-3

35. Eicosapentaenoic Acid (c20:5 N3)

36. Epa;timnodonic Acid

37. Icosapentaenoate

38. (all-z)-delta5,8,11,14,17-eicosapentaenoic Acid

39. C20:5n-3,6,9,12,15

40. Cis-5,8,11,14,17-epa

41. Fa 20:5

42. Ncgc00161344-03

43. C20:5 (n-3)

44. Eicosapentaenoic Acid (20:5 N-3)

45. Eicosa-5z,8z,11z,14z,17z-pentaenoic Acid (20:5, N-3)

46. Miraxion

47. Eicosapentanoic Acid

48. Eye Q

49. Eye-q

50. 5,8,11,14,17-eicosapentaenoic Acid, (5z,8z,11z,14z,17z)-

51. Epa [drug]

52. Unii-aan7qov9ea

53. 1553-41-9

54. Icosapentum [inn-latin]

55. Icosapento [inn-spanish]

56. (5z,8z,11z,14z,17z)-icosapentaenoate

57. Timnodonate

58. 3gwx

59. All Cis-5,8,11,14,17-eicosapentaenoic Acid

60. Mfcd00065716

61. All-cis-icosapentaenoate

62. All-cis-icosapentaenoic Acid

63. Dsstox_cid_21023

64. Dsstox_rid_79612

65. Dsstox_gsid_41023

66. Schembl20469

67. Bspbio_001328

68. Bml3-b01

69. Gtpl3362

70. Dtxsid9041023

71. Eicosapentaenoic Acid [mi]

72. Hms1361c10

73. Hms1791c10

74. Hms1989c10

75. Hms3402c10

76. Hms3649d19

77. Hy-b0660

78. Zinc4474603

79. 5,8,11,14,17-icosapentaenoate

80. Eicosapentaenoic Acid [inci]

81. Tox21_111991

82. 5,8,11,14,17-eicosapentaenoate

83. Bdbm50242349

84. Eicosapentaenoic Acid [vandf]

85. Lmfa01030759

86. S6476

87. Eicosapentaenoic Acid [mart.]

88. Akos027470327

89. Eicosapentaenoic Acid [usp-rs]

90. Eicosapentaenoic Acid [who-dd]

91. Ccg-207957

92. Ccg-208136

93. Db00159

94. Cis-5,8,11,14,17-eicosapentaenoate

95. Idi1_033798

96. Ncgc00161344-01

97. Ncgc00161344-02

98. Ncgc00161344-04

99. Ncgc00161344-07

100. 5z,8z,11z,14z,17z-eicosapentaenoate

101. Ac-31072

102. As-53730

103. Cas-10417-94-4

104. E0441

105. 5,8,11,14,17-eicosapentaenoic Acid (6ci)

106. All Cis-5,8,11,14,17-icosapentaenoic Acid

107. C06428

108. D08061

109. P16966

110. (all-cis)-5,8,11,14,17-eicosapentaenoic Acid

111. Eicosapentaenoic Acid (epa) (c20:5 N3)

112. L001256

113. Q409990

114. Sr-01000946647

115. Fa(20:5(5z,8z,11z,14z,17z))

116. J-001125

117. Sr-01000946647-1

118. Z,z,z,z,z-eicosa-5,8,11,14,17-pentaenoic Acid

119. (z,z,z,z,z)-5,8,11,14,17-eicosapentaenoic Acid

120. Brd-k47192521-001-02-1

121. Cis-5,8,11,14,17-eicosapentaenoic Acid, >=99%

122. 7f8bf016-b146-4f72-a52e-b9298ba3a9ab

123. C20h30o2 (cis-5,8,11,14,17-eicosapentaenoic Acid)

124. Eicosapentaenoic Acid, 5,8,11,14,17-(z,z,z,z,z)-

125. 5,8,11,14,17-eicosapentaenoic Acid, (all-z)- (8ci)

126. Cis-5,8,11,14,17-eicosapentaenoic Acid, >=85%, Liquid

127. Cis-5,8,11,14,17-eicosapentaenoic Acid, Analytical Standard

128. (5z,8z,11 Z,14z,17z)-icosa-5,8,11,14,17-pentaenoic Acid

129. (5z,8z,11z,14z,17z)-eicosa-5,8,11,14,17-pentaenoic Acid

130. Cis, Cis, Cis, Cis, Cis-eicosa-5,8,11,14,17-pentaenoic Acid

131. 5,8,11,14,17-eicosapentaenoic Acid, (5z,8z,11z,14z,17z)- (9ci)

132. Eicosapentaenoic Acid (epa) (c20:5) (constituent Of Krill Oil) [dsc]

133. Cis-5,8,11,14,17-eicosapentaenoic Acid, 500 Mug/ml In Ethanol, Certified Reference Material

2.4 Create Date
2005-03-26
3 Chemical and Physical Properties
Molecular Weight 302.5 g/mol
Molecular Formula C20H30O2
XLogP35.6
Hydrogen Bond Donor Count1
Hydrogen Bond Acceptor Count2
Rotatable Bond Count13
Exact Mass302.224580195 g/mol
Monoisotopic Mass302.224580195 g/mol
Topological Polar Surface Area37.3 Ų
Heavy Atom Count22
Formal Charge0
Complexity398
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count5
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

EPA can be used for lowering elevated triglycerides in those who are hyperglyceridemic. In addition, EPA may play a therapeutic role in patients with cystic fibrosis by reducing disease severity and may play a similar role in type 2 diabetics in slowing the progression of diabetic nephropathy.


FDA Label


OM3-CA is indicated as an adjunct to diet to reduce triglycerides levels in adults patients with severe hypertriglyceridemia (>500 mg/dL). The patients involved in this treatment should be laced with an appropriate lipid-lowering diet. Hypertriglyceridemia is defined as an elevated plasma triglyceride concentration. It is usually correlated to other secondary conditions such as poor diet, alcohol use, obesity, metabolic syndrome and type 2 diabetes.


FDA Label


Treatment of Familial Adenomatous Polyposis


Treatment of dyslipidaemia


5 Pharmacology and Biochemistry
5.1 Pharmacology

Eicosanoids are chemical messengers derived from 20-carbon polyunsaturated fatty acids that play critical roles in immune and inflammatory responses. Both 20-carbon omega-6 fatty acids (arachidonic acid) and 20-carbon omega-3 fatty acids (EPA) can be found in cell membranes. During an inflammatory response, arachidonic acid and EPA are metabolized by enzymes known as cyclooxygenases and lipoxygenases to form eicosanoids. Increasing omega-3 fatty acid intake increases the EPA content of cell membranes and decreases the arachidonic acid content, resulting in higher proportions of eicosanoids derived from EPA. Physiologic responses to arachidonic acid-derived eicosanoids differ from responses to EPA-derived eicosanoids. In general, eicosanoids derived from EPA are less potent inducers of inflammation, blood vessel constriction, and clotting than eicosanoids derived from arachidonic acid.


OM3-CA is very effective in reducing triglyceride levels. After 14 days of treatment, it is possible to observe even a 21% reduction. The reduction of the triglycerides could reach even to 25% in cases with the maximal used concentration of 4 g.


5.2 Absorption, Distribution and Excretion

Absorption

When compared to omega-3 -acid ethyl esters, OM3-CA present a 4-fold higher bioavailability. OM3-CA is absorbed directly in the small intestine and the maximal plasma concentration is reached between 4.5-5 hours after initial administration. The absorbed dosage is transferred to the general circulation via the lymphatic system and distributed within tissues throughout the body. The absorption speed and extent is highly promoted by the bile. In preclinical studies performed in dogs, the Cmax, tmax and AUC were reported to be 15.1 mcg/ml, 24 hours and 1210.3 mcg.h/ml, respectively.


Route of Elimination

OM3-CA does not go under renal excretion. After the metabolism, all the dose is excreted as CO2 and water in the form of expelled air and the rest is excreted in feces.


Volume of Distribution

This pharmacokinetic property is not available.


Clearance

The registered clearance rate at steady-state is of 548 ml/h for eicosapentaenoic acid and 518 ml/h for docohexaenoic acid.


5.3 Metabolism/Metabolites

OM3-CA is metabolized in the liver following the normal fatty acid oxidation. Once absorbed, they are incorporated into triglycerides, cholesterol esters and phospholipids in tissues. The metabolism is marked by beta-oxidation followed by tricarboxylic acid cycle. It is reported that OM3-CA is an inhibitor of several enzymes such as CYP2C9, CYP2C19 and to a lesser extent to CYP1A2, CYP2E1, CYP3A4. It is thought that the metabolism of OM3-CA is mainly done by CYP3A and CYP4F3B.


Eicosapentaenoic acid has known human metabolites that include Juniperonic acid.

S73 | METXBIODB | Metabolite Reaction Database from BioTransformer | DOI:10.5281/zenodo.4056560


5.4 Biological Half-Life

The half-life of OM3-CA depends on the type of component in which for eicosapentaenoic acid it is estimated to be of approximately 4.7-10.8 hours while for docosahexaenoic acid is reported to be of about 7 hours. The half-life of baseline-adjusted at steady-state is of 36 and 46 hours respectively for eicosapentaenoic acid and docosahexaenoic acid.


5.5 Mechanism of Action

The anti-inflammatory, antithrombotic and immunomodulatory actions of EPA is probably due to its role in eicosanoid physiology and biochemistry. Most eicosanoids are produced by the metabolism of omega-3 fatty acids, specifically, arachidonic acid. These eicosanoids, leukotriene B4 (LTB4) and thromboxane A2 (TXA2) stimulate leukocyte chemotaxis, platelet aggregation and vasoconstriction. They are thrombogenic and artherogenic. On the other hand, EPA is metabolized to leukotriene B5 (LTB5) and thromboxane A3 (TXA3), which are eicosanoids that promote vasodilation, inhibit platelet aggregation and leukocyte chemotaxis and are anti-artherogenic and anti-thrombotic. The triglyceride-lowering effect of EPA results from inhibition of lipogenesis and stimulation of fatty acid oxidation. Fatty acid oxidation of EPA occurs mainly in the mitochondria. EPA is a substrate for Prostaglandin-endoperoxide synthase 1 and 2. It also appears to affect the function and bind to the Carbohydrate responsive element binding protein (ChREBP) and to a fatty acid receptor (G-coupled receptor) known as GP40.


The reduction of the synthesis of triglycerides in the liver may be caused because the main components of OM3-CA, eicosapentaenoic acid, and docosahexaenoic acid, are poor substrates for the enzymes responsible for the synthesis of triglycerides. These two major components inhibit the esterification of other fatty acids. OM3-CA is also thought to enhance the clearance of triglycerides from the circulating very low-density lipoprotein particles by different potential effects such as inhibition of acyl-CoA:1,2-diacylglycerol acyltransferase, increase in mitochondrial and peroxisomal beta-oxidation in the liver, decrease lipogenesis in the liver and increase lipoprotein lipase activity.


USDMF

read-more
read-moreread-more

01

Finorga Sas

Germany
arrow
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothAxplora is your partner of choice for complex APIs.

Flag Germany
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2023-06-07

Pay. Date : 2023-06-05

DMF Number : 27182

Submission : 2013-05-23

Status : Active

Type : II

Axplora CB

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothChunghwa provides cost-effective APIs & advanced intermediates with complete DMF or COS, ensuring quality & reliable production.

Flag Taiwan
Digital Content Digital Content

GDUFA

DMF Review : Complete

Rev. Date : 2013-04-01

Pay. Date : 2012-11-20

DMF Number : 26271

Submission : 2012-08-01

Status : Active

Type : II

CCSB Company Banner

03

Ak Biopharm Co Ltd

South Korea

USDMF

arrow
AACR Annual meeting
Not Confirmed

03

Ak Biopharm Co Ltd

South Korea
arrow
AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 26946

Submission : 2013-03-04

Status : Active

Type : II

blank

04

Ak And Mn Biofarm Co Ltd

South Korea

USDMF

arrow
AACR Annual meeting
Not Confirmed

04

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 27998

Submission : 2014-02-10

Status : Active

Type : II

blank

05

Basf As

Germany

USDMF

arrow
AACR Annual meeting
Not Confirmed

05

Basf As

Germany
arrow
AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2020-11-02

Pay. Date : 2020-10-20

DMF Number : 23911

Submission : 2010-07-07

Status : Active

Type : II

blank

06

AACR Annual meeting
Not Confirmed

06

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 25289

Submission : 2011-09-12

Status : Inactive

Type : II

blank

07

Chemport Inc

United Kingdom

USDMF

arrow
AACR Annual meeting
Not Confirmed

07

Chemport Inc

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 22077

Submission : 2008-10-09

Status : Inactive

Type : II

blank

08

Kd Pharma Bexbach Gmbh

Germany

USDMF

arrow
AACR Annual meeting
Not Confirmed

08

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2013-08-21

Pay. Date : 2013-02-27

DMF Number : 26892

Submission : 2013-02-26

Status : Active

Type : II

blank

09

Kd Pharma Bexbach Gmbh

Germany

USDMF

arrow
AACR Annual meeting
Not Confirmed

09

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : Complete

Rev. Date : 2015-02-20

Pay. Date : 2014-04-09

DMF Number : 28140

Submission : 2014-03-31

Status : Active

Type : II

blank

10

Nissui Corporation

Japan

USDMF

arrow
AACR Annual meeting
Not Confirmed

10

AACR Annual meeting
Not Confirmed

GDUFA

DMF Review : N/A

Rev. Date :

Pay. Date :

DMF Number : 22474

Submission : 2009-01-23

Status : Active

Type : II

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

JDMF

read-more
read-moreread-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

AK&MN Biofarm Icosapentate (raw material) (for export)

Registration Number : 227MF10010

Registrant's Address : #81, Sanggae-Ro, Nam-Gu, Ulsan, Korea

Initial Date of Registration : 2015-01-05

Latest Date of Registration : 2015-01-05

blank

02

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Maxomega EPA97EE

Registration Number : 223MF10118

Registrant's Address : 4th and 5th Floors, 2 Stockport Exchange, Railway Road, Stockport, SK1 3GG, UK

Initial Date of Registration : 2011-07-25

Latest Date of Registration : 2025-09-11

blank

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Icosapent San EQ

Registration Number : 217MF10441

Registrant's Address : 363 Tokutomi, Akaiwa City, Okayama Prefecture

Initial Date of Registration : 2005-08-19

Latest Date of Registration : 2020-06-11

blank

04

Chemport Inc.

United Kingdom
AACR Annual meeting
Not Confirmed
arrow

Chemport Inc.

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

Ethyl eicosapentate

Registration Number : 227MF10158

Registrant's Address : 30-5 Dongsunonggongdanji-gil, Naju-si, Jeollanam-do 58275, Korea

Initial Date of Registration : 2015-06-18

Latest Date of Registration : 2016-07-15

blank

05

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Ethyl eicosapentate

Registration Number : 303MF10106

Registrant's Address : No. 37 Section 6, North Chengdu Avenue, Guanghan, Deyang City, Sichuan Province P. R....

Initial Date of Registration : 2021-07-09

Latest Date of Registration : 2023-08-09

blank

06

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Ethyl eicosapentate

Registration Number : 228MF10081

Registrant's Address : Am Kraftwerk 6,66450 Bexbach, Germany

Initial Date of Registration : 2016-04-06

Latest Date of Registration : 2016-04-06

blank

07

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Ethyl eicosapentate

Registration Number : 303MF10048

Registrant's Address : Am Kraftwerk 6,66450 Bexbach, Germany

Initial Date of Registration : 2021-03-17

Latest Date of Registration : 2021-03-17

blank

08

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

EPA-E "Nissin"

Registration Number : 217MF11111

Registrant's Address : 1-25 Kanda Nishikicho, Chiyoda-ku, Tokyo

Initial Date of Registration : 2005-12-05

Latest Date of Registration : 2023-09-13

blank

09

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ETHYL ICO SAPENTATE

Registration Number : 305MF10044

Registrant's Address : No. 1, Lutai Road, High-tech District, Zibo, Shandong, P. R. China

Initial Date of Registration : 2023-04-05

Latest Date of Registration : 2023-04-05

blank

10

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

EPA-E Tama

Registration Number : 217MF10180

Registrant's Address : 1-23-3 Nishi-Shinjuku, Shinjuku-ku, Tokyo

Initial Date of Registration : 2005-06-06

Latest Date of Registration : 2007-03-05

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

KDMF

read-more
read-moreread-more

01

AK BIOPHARM

South Korea
AACR Annual meeting
Not Confirmed
arrow

AK BIOPHARM

South Korea
arrow
AACR Annual meeting
Not Confirmed

ethyl icosapentate

Registrant Name : Aekyung Biopharm Co., Ltd.

Registration Date : 2024-06-28

Registration Number : 20240628-211-J-1661

Manufacturer Name : Aekyung Biopharm Co., Ltd.

Manufacturer Address : 81 Sanggae-ro, Nam-gu, Ulsan (80, 80A)

blank

02

Chemport Inc

United Kingdom
AACR Annual meeting
Not Confirmed
arrow

Chemport Inc

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

Ethyl eicosapentate

Registrant Name : Chemport Co., Ltd.

Registration Date : 2022-08-22

Registration Number : 20220822-211-J-1348

Manufacturer Name : Chemport Co., Ltd.

Manufacturer Address : Laboratory: 30-51, Dongsunonggongdanji-gil, Naju-si, Jeollanam-do; 2nd Floor, Researc...

blank

03

KD Pharma Group

Switzerland
AACR Annual meeting
Not Confirmed
arrow

KD Pharma Group

Switzerland
arrow
AACR Annual meeting
Not Confirmed

ethyl icosapentate

Registrant Name : Aging Life Science Co., Ltd.

Registration Date : 2024-02-23

Registration Number : 20240223-211-J-1613

Manufacturer Name : KD Pharma Bexbach GmbH @ KD ...

Manufacturer Address : Am Kraftwerk 6 - 8 66450 Bexbach Germany@Fabrikstraße 51 66424 Homburg Germany

blank

04

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ethyl icosapentate

Registrant Name : MPK Korea Co., Ltd.

Registration Date : 2025-04-15

Registration Number : 20250415-211-J-1850

Manufacturer Name : Shandong Xinhua Pharmaceutic...

Manufacturer Address : Hutian Chemical Industrial Zone, Zibo, Shandong, China

blank

05

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ethyl icosapentate

Registrant Name : Poonglim Pharmaceutical Co., Ltd.

Registration Date : 2025-12-29

Registration Number : 20250415-211-J-1850(1)

Manufacturer Name : Shandong Xinhua Pharmaceutic...

Manufacturer Address : Hutian Chemical Industrial Zone, Zibo, Shandong, China

blank

06

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ethyl icosapentate

Registrant Name : Ace Biopharm Co., Ltd.

Registration Date : 2025-04-21

Registration Number : 20250421-211-J-1869

Manufacturer Name : Zhejiang Medicine Co., Ltd. ...

Manufacturer Address : 98 East Xinchang Dadao Road, Xinchang, Zhejiang, PR China,312500

blank

07

AACR Annual meeting
Not Confirmed
arrow

arrow
AACR Annual meeting
Not Confirmed

ethyl icosapentate

Registrant Name : V-On Bio Co., Ltd.

Registration Date : 2025-11-04

Registration Number : 20251104-211-J-2032

Manufacturer Name : Nissui Corporation, Kashima ...

Manufacturer Address : 18-2, HigashiFukashiba, Kamis, Ibaraki 314-0103, Japan

blank

08

AACR Annual meeting
Not Confirmed
arrow

arrow
AACR Annual meeting
Not Confirmed

ethyl icosapentate

Registrant Name : V-On Bio Co., Ltd.

Registration Date : 2025-11-04

Registration Number : 20251104-211-J-2033

Manufacturer Name : Nissui Corporation, Tsukuba ...

Manufacturer Address : 7, Okubo, Tsukuba-shi, Ibaraki 300-2611, Japan

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more

Details:

Dr Reddy's Laboratories announced the launch of Icosapent Ethyl Capsules, used to reduce triglyceride (TG) levels in adult patients, in the US market. Dr Reddy's Icosapent Ethyl is available in 1 gram capsules in bottle count size of 120's count.


Lead Product(s): Icosapent Ethyl,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 22, 2021

Dr Reddy Company Banner

01

Lead Product(s) : Icosapent Ethyl,Inapplicable

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Dr Reddy's Laboratories announced the launch of Icosapent Ethyl Capsules, used to reduce triglyceride (TG) levels in adult patients, in the US market. Dr Reddy's Icosapent Ethyl is available in 1 gram capsules in bottle count size of 120's count.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 22, 2021

Dr Reddy Company Banner

Details:

Vascepa-Generic (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA) which is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina.


Lead Product(s): Icosapent Ethyl

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vascepa-Generic

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Amneal Pharmaceuticals

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 02, 2023

Strides Pharma Science

02

Lead Product(s) : Icosapent Ethyl

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Amneal Pharmaceuticals

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Vascepa-Generic (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA) which is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina.

Product Name : Vascepa-Generic

Product Type : Miscellaneous

Upfront Cash : Inapplicable

December 02, 2023

Strides Pharma Science

Details:

Icosapent ethyl capsules is an ethyl ester of eicosapentaenoic acid (EPA), which is indicated for the treatment of to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina in adult patients with elevated triglyceride.


Lead Product(s): Icosapent Ethyl

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vascepa-Generic

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 03, 2023

Strides Pharma Science

03

Lead Product(s) : Icosapent Ethyl

Therapeutic Area : Cardiology/Vascular Diseases

Highest Development Status : Approved FDF

Partner/Sponsor/Collaborator : Undisclosed

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Icosapent ethyl capsules is an ethyl ester of eicosapentaenoic acid (EPA), which is indicated for the treatment of to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina in adult patients with elevated trigly...

Product Name : Vascepa-Generic

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 03, 2023

Strides Pharma Science

Details:

Eicosapentaenoic Acid is a small molecule drug, which is currently being evaluated in clinical studies for the treatment of undisclosed medical condition.


Lead Product(s): Icosapent Ethyl,Levomefolate Calcium

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 10, 2026

blank

04

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Details : Eicosapentaenoic Acid is a small molecule drug, which is currently being evaluated in clinical studies for the treatment of undisclosed medical condition.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 10, 2026

blank
  • Development Update

Details:

Ruby-O (Phospholipid Omega-3) is a dietary supplement drug, which is currently being evaluated in clinical studies for the treatment of dyslipidemias.


Lead Product(s): Phospholipid Omega-3,Icosapent Ethyl,DHA

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Ruby-O

Study Phase: UndisclosedProduct Type: Dietary Supplement

Sponsor: C.I. NATURMEGA S.A.

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 06, 2026

blank

05

Fundación del Caribe para la Investigación Biomédica

Country
arrow
AACR Annual meeting
Not Confirmed

Fundación del Caribe para la Investigación Biomédica

Country
arrow
AACR Annual meeting
Not Confirmed

Details : Ruby-O (Phospholipid Omega-3) is a dietary supplement drug, which is currently being evaluated in clinical studies for the treatment of dyslipidemias.

Product Name : Ruby-O

Product Type : Dietary Supplement

Upfront Cash : Inapplicable

February 06, 2026

blank
  • Development Update

Details:

Vitamin B is a vitamins/minerals/inorganic salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Dementia.


Lead Product(s): Niacinamide,Folic Acid,Riboflavin,Icosapent Ethyl,DHA

Therapeutic Area: Neurology Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Vitamins/Minerals/Inorganic Salts

Sponsor: Aker BioMarine

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable December 31, 2025

blank

06

University of Oslo

Country
arrow
AACR Annual meeting
Not Confirmed

University of Oslo

Country
arrow
AACR Annual meeting
Not Confirmed

Details : Vitamin B is a vitamins/minerals/inorganic salts drug candidate, which is currently being evaluated in clinical studies for the treatment of Dementia.

Product Name : Undisclosed

Product Type : Vitamins/Minerals/Inorganic Salts

Upfront Cash : Inapplicable

December 31, 2025

blank

Details:

Under the licensing agreement, Recordati will be responsible for commercialization of Vazkepa (Icosapent Ethyl) in Europe. It is being indicated to reduce the risk of myocardial infarction, stroke.


Lead Product(s): Icosapent Ethyl,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vascepa

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Recordati

Deal Size: $175.0 million Upfront Cash: $25.0 million

Deal Type: Licensing Agreement June 24, 2025

blank

07

Amarin

Ireland
arrow
AACR Annual meeting
Not Confirmed

Amarin

Ireland
arrow
AACR Annual meeting
Not Confirmed

Details : Under the licensing agreement, Recordati will be responsible for commercialization of Vazkepa (Icosapent Ethyl) in Europe. It is being indicated to reduce the risk of myocardial infarction, stroke.

Product Name : Vascepa

Product Type : Miscellaneous

Upfront Cash : $25.0 million

June 24, 2025

blank
  • Development Update

Details:

Eicosapentaenoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypertriglyceridemia.


Lead Product(s): Icosapent Ethyl,Hydroxytyrosol

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Miscellaneous

Sponsor: Beps Holding GmbH | Olivenova Health Sl

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable May 28, 2025

blank

08

National Research Council, Spain

Country
arrow
AACR Annual meeting
Not Confirmed

National Research Council, Spain

Country
arrow
AACR Annual meeting
Not Confirmed

Details : Eicosapentaenoic Acid is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of Hypertriglyceridemia.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

May 28, 2025

blank

Details:

Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.


Lead Product(s): Fish Oil,Icosapent Ethyl,L-5- Methyltetrahydrofolate

Therapeutic Area: Undisclosed Brand Name: Undisclosed

Study Phase: UndisclosedProduct Type: Dietary Supplement

Sponsor: Glogen Clinical Research Pvt. Ltd

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 06, 2025

blank

09

AACR Annual meeting
Not Confirmed
AACR Annual meeting
Not Confirmed

Lead Product(s) : Fish Oil,Icosapent Ethyl,L-5- Methyltetrahydrofolate

Therapeutic Area : Undisclosed

Highest Development Status : Undisclosed

Partner/Sponsor/Collaborator : Glogen Clinical Research Pvt. Ltd

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Fish Oil is a Dietary Supplement drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

Product Name : Undisclosed

Product Type : Dietary Supplement

Upfront Cash : Inapplicable

January 06, 2025

blank

Details:

Vascepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA) which is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina.


Lead Product(s): Icosapent Ethyl,Inapplicable

Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Vascepa

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable July 08, 2024

blank

10

Edding Pharm

China
arrow
AACR Annual meeting
Not Confirmed

Edding Pharm

China
arrow
AACR Annual meeting
Not Confirmed

Details : Vascepa (icosapent ethyl) is an ethyl ester of eicosapentaenoic acid (EPA) which is indicated to reduce the risk of myocardial infarction, stroke, coronary revascularization, and unstable angina.

Product Name : Vascepa

Product Type : Miscellaneous

Upfront Cash : Inapplicable

July 08, 2024

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDF Dossiers

read-more
read-more

01

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Regulatory Info : RX

Registration Country : USA

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 1GM

Packaging :

Approval Date : 2020-08-07

Application Number : 209499

Regulatory Info : RX

Registration Country : USA

Dr Reddy Company Banner

02

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

Regulatory Info : RX

Registration Country : USA

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 500MG

Packaging :

Approval Date : 2023-03-08

Application Number : 209499

Regulatory Info : RX

Registration Country : USA

Dr Reddy Company Banner

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 500MG

Packaging :

Approval Date : 2023-12-07

Application Number : 216811

Regulatory Info : RX

Registration Country : USA

blank

04

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 1GM

Packaging :

Approval Date : 2024-02-16

Application Number : 216811

Regulatory Info : RX

Registration Country : USA

blank

05

Amarin

Ireland
AACR Annual meeting
Not Confirmed
arrow

Amarin

Ireland
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : VASCEPA

Dosage Form : CAPSULE;ORAL

Dosage Strength : 1GM

Packaging :

Approval Date : 2012-07-26

Application Number : 202057

Regulatory Info : RX

Registration Country : USA

blank

06

Amarin

Ireland
AACR Annual meeting
Not Confirmed
arrow

Amarin

Ireland
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : VASCEPA

Dosage Form : CAPSULE;ORAL

Dosage Strength : 500MG

Packaging :

Approval Date : 2017-02-16

Application Number : 202057

Regulatory Info : RX

Registration Country : USA

blank

07

Apotex Inc

Canada
AACR Annual meeting
Not Confirmed
arrow

Apotex Inc

Canada
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 1GM

Packaging :

Approval Date : 2021-06-30

Application Number : 209437

Regulatory Info : RX

Registration Country : USA

blank

08

Hikma Pharmaceuticals

United Kingdom
AACR Annual meeting
Not Confirmed
arrow

Hikma Pharmaceuticals

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 1GM

Packaging :

Approval Date : 2020-05-21

Application Number : 209457

Regulatory Info : RX

Registration Country : USA

blank

09

Hikma Pharmaceuticals

United Kingdom
AACR Annual meeting
Not Confirmed
arrow

Hikma Pharmaceuticals

United Kingdom
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 500MG

Packaging :

Approval Date : 2023-03-08

Application Number : 209457

Regulatory Info : RX

Registration Country : USA

blank

10

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 500MG

Packaging :

Approval Date : 2020-09-11

Application Number : 209525

Regulatory Info : RX

Registration Country : USA

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

FDA Orange Book

read-more
read-more

01

DR REDDYS

India
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

RLD : No

TE Code : AB

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 1GM

Approval Date : 2020-08-07

Application Number : 209499

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

Dr Reddy Company Banner

02

DR REDDYS

India
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothDRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Flag India
Digital Content Digital Content

RLD : No

TE Code : AB

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 500MG

Approval Date : 2023-03-08

Application Number : 209499

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

Dr Reddy Company Banner

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 500MG

Approval Date : 2023-12-07

Application Number : 216811

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank

04

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 1GM

Approval Date : 2024-02-16

Application Number : 216811

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank

05

AMARIN PHARMS

Ireland
AACR Annual meeting
Not Confirmed
arrow

AMARIN PHARMS

Ireland
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : VASCEPA

Dosage Form : CAPSULE;ORAL

Dosage Strength : 1GM

Approval Date : 2012-07-26

Application Number : 202057

RX/OTC/DISCN : RX

RLD : Yes

TE Code : AB

blank

06

AMARIN PHARMS

Ireland
AACR Annual meeting
Not Confirmed
arrow

AMARIN PHARMS

Ireland
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : VASCEPA

Dosage Form : CAPSULE;ORAL

Dosage Strength : 500MG

Approval Date : 2017-02-16

Application Number : 202057

RX/OTC/DISCN : RX

RLD : Yes

TE Code : AB

blank

07

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 1GM

Approval Date : 2025-08-06

Application Number : 219156

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank

08

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 1GM

Approval Date : 2023-12-22

Application Number : 217919

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank

09

QILU

China
AACR Annual meeting
Not Confirmed
arrow

QILU

China
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 1GM

Approval Date : 2024-11-20

Application Number : 218899

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank

10

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

ICOSAPENT ETHYL

Brand Name : ICOSAPENT ETHYL

Dosage Form : CAPSULE;ORAL

Dosage Strength : 500MG

Approval Date : 2023-04-20

Application Number : 217656

RX/OTC/DISCN : RX

RLD : No

TE Code : AB

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Europe

read-more
read-more

01

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Icosapent ethyl

Brand Name : Vazkepa

Dosage Form : Capsule

Dosage Strength : 998mg

Packaging :

Approval Date :

Application Number :

Regulatory Info : Prescription

Registration Country : Estonia

blank

02

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Ethyl Icosapent

Brand Name : Vazkepa

Dosage Form : Soft Capsule

Dosage Strength : 998MG

Packaging :

Approval Date : 29-07-2021

Application Number : 1201524001

Regulatory Info : Authorized

Registration Country : Spain

blank

03

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Eicosapentaenoic Acid; Docosahexaenoic Acid

Brand Name : Burgerstein EPA-Kapseln

Dosage Form : Capsule

Dosage Strength :

Packaging :

Approval Date : 23/05/1990

Application Number : 49417

Regulatory Info : Allowed

Registration Country : Switzerland

blank

04

AACR Annual meeting
Not Confirmed
arrow
arrow
AACR Annual meeting
Not Confirmed

Eicosapentaenoic Acid; Docosahexaenoic Acid; Purified Egg Phospholipids; Glycerol; RRR-Alpha-Tocopherol

Brand Name : Omegaven-Fresenius

Dosage Form : Infusion Emulsion

Dosage Strength :

Packaging :

Approval Date : 29/03/1999

Application Number : 54750

Regulatory Info : Allowed

Registration Country : Switzerland

blank

05

Guerbet

France
AACR Annual meeting
Not Confirmed
arrow

Guerbet

France
arrow
AACR Annual meeting
Not Confirmed

Icosapent Ethyl

Brand Name : Hevascol

Dosage Form : Injectable Solution

Dosage Strength : 480mgI/ml

Packaging :

Approval Date : 21-02-2023

Application Number : 2.02E+13

Regulatory Info : Approved

Registration Country : Sweden

blank

06

Amarin Pharmaceuticals Ireland Limited

Country
AACR Annual meeting
Not Confirmed
arrow

Amarin Pharmaceuticals Ireland Limited

Country
arrow
AACR Annual meeting
Not Confirmed

Icosapent(Epa)Ethylester

Brand Name : Vazkepa

Dosage Form : Soft Capsule

Dosage Strength : 998mg

Packaging :

Approval Date : 26-03-2021

Application Number : 28106363219

Regulatory Info : Prescription

Registration Country : Denmark

blank
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Parenteral

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Solubilizers

read-more
read-more

Taste Masking

read-more
read-more

Topical

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Empty Capsules

read-more
read-more

Coating Systems & Additives

read-more
read-more

API Stability Enhancers

read-more
read-more

Emulsifying Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Direct Compression

read-more
read-more

Surfactant & Foaming Agents

read-more
read-more

Co-Processed Excipients

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Lubricants & Glidants

read-more
read-more

Soft Gelatin

read-more
read-more

Rheology Modifiers

read-more
read-more

Controlled & Modified Release

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

REF. STANDARDS & IMPURITIES

Upload your portfolio for free, ask us

ABOUT THIS PAGE

Looking for 10417-94-4 / Icosapent Ethyl API manufacturers, exporters & distributors?

Icosapent Ethyl manufacturers, exporters & distributors 1

42

PharmaCompass offers a list of Icosapent Ethyl API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Icosapent Ethyl manufacturer or Icosapent Ethyl supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Icosapent Ethyl manufacturer or Icosapent Ethyl supplier.

API | Excipient name

Icosapent Ethyl

Synonyms

Timnodonic acid, Icosapent, 10417-94-4, Icosapentaenoic acid, Epa, Cis-5,8,11,14,17-eicosapentaenoic acid

Cas Number

10417-94-4

Unique Ingredient Identifier (UNII)

AAN7QOV9EA

About Icosapent Ethyl

Important polyunsaturated fatty acid found in fish oils. It serves as the precursor for the prostaglandin-3 and thromboxane-3 families. A diet rich in eicosapentaenoic acid lowers serum lipid concentration, reduces incidence of cardiovascular disorders, prevents platelet aggregation, and inhibits arachidonic acid conversion into the thromboxane-2 and prostaglandin-2 families.

Eicosapentaenoic Acid Manufacturers

A Eicosapentaenoic Acid manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Eicosapentaenoic Acid, including repackagers and relabelers. The FDA regulates Eicosapentaenoic Acid manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Eicosapentaenoic Acid API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Eicosapentaenoic Acid manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Eicosapentaenoic Acid Suppliers

A Eicosapentaenoic Acid supplier is an individual or a company that provides Eicosapentaenoic Acid active pharmaceutical ingredient (API) or Eicosapentaenoic Acid finished formulations upon request. The Eicosapentaenoic Acid suppliers may include Eicosapentaenoic Acid API manufacturers, exporters, distributors and traders.

click here to find a list of Eicosapentaenoic Acid suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Eicosapentaenoic Acid USDMF

A Eicosapentaenoic Acid DMF (Drug Master File) is a document detailing the whole manufacturing process of Eicosapentaenoic Acid active pharmaceutical ingredient (API) in detail. Different forms of Eicosapentaenoic Acid DMFs exist exist since differing nations have different regulations, such as Eicosapentaenoic Acid USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Eicosapentaenoic Acid DMF submitted to regulatory agencies in the US is known as a USDMF. Eicosapentaenoic Acid USDMF includes data on Eicosapentaenoic Acid's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Eicosapentaenoic Acid USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Eicosapentaenoic Acid suppliers with USDMF on PharmaCompass.

Eicosapentaenoic Acid JDMF

The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.

The Eicosapentaenoic Acid Drug Master File in Japan (Eicosapentaenoic Acid JDMF) empowers Eicosapentaenoic Acid API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).

PMDA reviews the Eicosapentaenoic Acid JDMF during the approval evaluation for pharmaceutical products. At the time of Eicosapentaenoic Acid JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.

click here to find a list of Eicosapentaenoic Acid suppliers with JDMF on PharmaCompass.

Eicosapentaenoic Acid KDMF

In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.

Pharmaceutical companies submit a Eicosapentaenoic Acid Drug Master File in Korea (Eicosapentaenoic Acid KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Eicosapentaenoic Acid. The MFDS reviews the Eicosapentaenoic Acid KDMF as part of the drug registration process and uses the information provided in the Eicosapentaenoic Acid KDMF to evaluate the safety and efficacy of the drug.

After submitting a Eicosapentaenoic Acid KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Eicosapentaenoic Acid API can apply through the Korea Drug Master File (KDMF).

click here to find a list of Eicosapentaenoic Acid suppliers with KDMF on PharmaCompass.

Eicosapentaenoic Acid GMP

Eicosapentaenoic Acid Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Eicosapentaenoic Acid GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Eicosapentaenoic Acid GMP manufacturer or Eicosapentaenoic Acid GMP API supplier for your needs.

Eicosapentaenoic Acid CoA

A Eicosapentaenoic Acid CoA (Certificate of Analysis) is a formal document that attests to Eicosapentaenoic Acid's compliance with Eicosapentaenoic Acid specifications and serves as a tool for batch-level quality control.

Eicosapentaenoic Acid CoA mostly includes findings from lab analyses of a specific batch. For each Eicosapentaenoic Acid CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Eicosapentaenoic Acid may be tested according to a variety of international standards, such as European Pharmacopoeia (Eicosapentaenoic Acid EP), Eicosapentaenoic Acid JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Eicosapentaenoic Acid USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty